Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL29981811 | 0.99 | KDM4E (0.32) | KDM4EALDH1A1HPGDSMN1; SMN2PTGS1 | |
| SCHEMBL24860256 | 0.79 | PTGS1 (0.32) | KDM4EALDH1A1PTGS1PTGS2 | |
| SCHEMBL24934670 | 0.67 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL24934671 | 0.67 | PIK3C3 (0.42) | PTGS1PTGS2 | |
| SCHEMBL21887773 | 0.62 | PTGS2 (0.34) | PTGS1PTGS2 | |
| SCHEMBL24934387 | 0.59 | PDK1 (0.41) | — | |
| SCHEMBL24934563 | 0.59 | PDK2 (0.46) | — | |
| SCHEMBL16487838 | 0.59 | PTGS1 (0.51) | KDM4EALDH1A1PTGS1PTGS2 | |
| SCHEMBL3132967 | 0.59 | PTGS2 (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2PTGS1 | |
| SCHEMBL758276 | 0.57 | RAB9A (0.37) | KDM4EALDH1A1HPGDSMN1; SMN2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151543-B | Fused tricyclic compounds and medical uses thereof | 日本烟草产业株式会社 | 2024-12-17 | — | — | CN | disclosed |
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025880-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | PC, PCK2, AGK | KDM4E 4747/4885ALDH1A1 907/4885HPGD 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.